新诺威:控股子公司SYS6041抗体偶联药物获得美国药物临床试验批准

美港电讯
14 Apr

【新诺威:控股子公司SYS6041抗体偶联药物获得美国药物临床试验批准】金十数据4月14日讯,新诺威公告称,公司控股子公司巨石生物收到FDA通知,注射用SYS6041药品临床试验申请已获批准,可在美国开展临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10